The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC

NCT06965829 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer Stage III

Interventions

DRUG: Tislelizumab
DRUG: Carboplatin and Paclitaxel and Radiation Therapy

Sponsor

Shanghai Chest Hospital